Abstract. This paper presents diagnostic criteria for Menière's disease
orders MD -Meniere's disease SNHL -Sensorineural hearing loss MRI -Magnetic resonance imaging TIA -Transient ischemic attacks
Introduction
Menière's disease (MD) is a multifactorial disorder where the combined effect of genetics and environmental factors probably determine the onset of the disease. It is associated with the accumulation of endolymph in the cochlear duct and the vestibular organs in histopathological studies [1] , although endolymphatic hydrops (EH) per se does not explain all clinical features, including the progression of hearing loss or the frequency of attacks of vertigo [2] . Menière's disease is a clinical syndrome that consists of episodes of spontaneous vertigo usually associated with unilateral fluctuating sensorineural hearing loss (SNHL), tinnitus and aural fullness. Cochlear symptoms may also occur between vertigo episodes. The episodes of vertigo are usually much more common in the first years of the disease, but hearing loss and vestibular hypofunction show a great variability among patients, making the phenotyping of MD difficult. A taxonomy of MD subtypes is needed to help categorize individuals who manifest what may be incomplete phenotypes. Moreover, subsets of patients have been described who develop bilateral SNHL and other co-morbidities such as migraine, benign paroxysmal positional vertigo and systemic autoimmune diseases, further complicating the diagnosis and management in these cases.
The Bárány Society, which represents the international community of basic scientists, otolaryngologists, oto-neurologists, physical therapists and other experts committed to vestibular research, has set up a Classification Committee for an International Classification of Vestibular Disorders (ICVD). Individual disorders are defined by classification groups, which include otolaryngologists and neurologists from at least three continents. The ICVD has been organized in 3 levels: signs and symptoms, vestibular syndromes and diseases. As a first step and prerequisite for defining major syndromes and diseases of the ICVD, the Classification Committee of the Bárány Society (CCBS) has published a consensus on the definitions of vestibular symptoms [3] . Further, a consensus document of the Bárány Society and the International Headache Society was published to define the diagnostic criteria of vestibular migraine [4] . Current ongoing works include definition for vestibular signs such as nystagmus, benign paroxysmal positional vertigo, unilateral and bilateral vestibulopathy and vestibular paroxysmia.
Different efforts have been sought to define in the past a consensus diagnosis for MD. The Japanese Society for Equilibrium Research proposed clinical criteria for diagnosis of MD in 1974 (Appendix 1). The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) developed the guidelines for diagnosis and therapy evaluation of MD in 1972 and revised them in 1985 and 1995 [5] . These guidelines have been widely used in clinical research, and nearly all studies published since 1995 are based on these criteria (Appendix 2). Despite the great contribution of these guidelines to evaluate the effectiveness of medical and surgical treatments for MD, no biological marker for diagnosis or prognosis has been identified for MD so far, but an evolving understanding of MD and vestibular migraine -the most relevant differential diagnosis -points out the need to update these criteria. The clinical variability observed in MD makes it necessary to improve the precision to characterize clinical findings during and between the episodes of vertigo and the recognition of a familial history of hearing loss and episodic vertigo. These will lead to more homogeneous cohorts of patients to conduct clinical multicenter studies, including large-scale genomic studies. The EAONO had also established a working group to prepare European guidelines for diagnosis and treatment of MD.
The principal aim of this effort has been to develop international consensus diagnostic criteria for MD as part of the ongoing work of the CCBS to improve the quality of clinical data obtained from patients to facilitate collaborative studies.
Methods
This work forms part of an ongoing multi-year project to develop an ICVD, which uses a structured process for developing international consensus definitions for vestibular symptoms, syndromes, disorders, and diseases. This process, overseen by the CCBS, is based on expert, multi-disciplinary committees with international representation developing diagnostic criteria for subsequent comment and refinement prior to publication. These criteria are built on a critical appraisal of current best scientific evidence. A collaborative work among the Equilibrium Committee of the AAO-HNS, the Japan Society for Equilibrium Research, the EAONO, the Korean Balance Society and the Bárány Society has been established for joint development of diagnostic criteria for MD. All definitions are supported by notes, comments, and written discussion according to a template established by the CCBS for ICVD. MD criteria were developed iteratively over a four-year period (2010-14) through discussion, presentation, and refinement. Two diagnostic categories were considered: definite and probable MD. The primary adjustments to prior criteria were to clarify the nature of auditory symptoms and signs present for definite MD.
Criteria for diagnosis of Menière's disease

Previously used terms: Menière's syndrome, endolymphatic hydrops (EH)
Definite MD
A. Two or more spontaneous episodes of vertigo (1, 2) , each lasting 20 minutes to 12 hours (3) . B. Audiometrically documented low-to mediumfrequency sensorineural hearing loss (4, 5) in one ear, defining the affected ear on at least one occasion before, during or after one of the episodes of vertigo (6, 7) . C. Fluctuating aural symptoms (hearing, tinnitus or fullness) in the affected ear (8) . D. Not better accounted for by another vestibular diagnosis (9) .
Notes:
(1) Vertigo is the sensation of self-motion when no self-motion is occurring or the sensation of distorted self-motion during an otherwise normal head movement [3] . Episodic dizziness and unsteadiness are not considered as criteria to define MD, although patients with MD can report dizziness and unsteadiness at long term. (2) Although most patients report entirely spontaneous spells of vertigo, some patients identify dietary triggers, such as excessive consumption of sodium or caffeine. Some patients can experience episodes of vertigo lasting seconds to minutes triggered by high intensity and lowfrequency sound (Tullio phenomenon) and by changes in pressure. These episodes tend to occur later in the disease, perhaps as a result of advanced hydrops bringing the membranous labyrinth in close proximity to the stapes footplate.
(3) The duration of the episodes is defined by the time that the patient has to be on rest and cannot move. It may last less than 20 minutes or more than 12 hours, but neither is a common finding, and other disorders should be considered when such durations are noted [6] . When short episodes occur they are usually spontaneous. Brief episodes triggered by positional changes of the head should suggest other causes such as BPPV. can occur in some patients [7] [8] [9] , although such a pattern should raise concern for the possibility of autoimmune inner ear disease [10] and when progressing slowly over years, may favor migraine as an alternate explanation for the vertigo episodes or a comorbid condition [11] . Bilateral low-frequency SNHL can also been observed in early stages of non-syndromic progressive deafness (DFNA6/14) due to mutations in the WFS1 gene, but vertigo attacks have not been associated with this group of mutations [12] . SNHL in MD can also involve middle and high frequencies after several episodes of vertigo, leading to pan-tonal hearing loss. (5) Non-simultaneous onset of vertigo and hearing loss. Sensorineural hearing loss may antedate the onset of vertigo episodes by several months or years. This clinical variant has been called "delayed hydrops" [13, 14] , but the preferred term should be delayed MD, since EH is a pathological finding. Episodic vertigo may precede the onset of hearing loss by several weeks or months, but tinnitus or aural fullness is usually associated with the first episode of vertigo. 
Probable MD
A. Two or more episodes of vertigo or dizziness, each lasting 20 minutes to 24 hours. B. Fluctuating aural symptoms (hearing, tinnitus or fullness) in the affected ear (1) . D. Not better accounted for by another vestibular diagnosis (2) .
Notes:
(1) Fluctuating symptoms must be reported during the vertigo episode. Sensorineural hearing loss is usually found, but conductive or mixed hearing loss may be also observed in the first years of the disease. An increase in tinnitus intensity or aural fullness in the affected ear is usually associated with the episode of vertigo in the first years. 
Comments
Epidemiology
The prevalence of MD is approximately 34-190 per 100.000 [17] [18] [19] . The age of onset ranges from the third to the seventh decades of life with a small female predominance. The odds of MD are greater for older subjects (adjusted OR per 10-year increase: 1.5), white ethnicity (OR 1.7) and severe obesity (OR 1.7) [19] . Furthermore, MD is associated with several comorbid conditions such as arthritis (OR 1.8), psoriasis (OR 1.8), gastroesophageal reflux disease (OR 1.5), irritable bowel syndrome (OR 2.1) and migraine (OR 2.0) [19] . MD is characterized by a variable course, and the development of cochlear and vestibular symptoms may take years in individual patients [20] . A list of disorders mimicking MD is presented in Table 1 .
Endolymphatic hydrops (EH)
Histopathological studies in human temporal bones have found EH in most patients with MD [1, 2] . The recent development of 3 T MRI with gadolinium chelate has allowed the visualization of EH in 93% of ears with symptoms attributable to MD, but also in 65% of asymptomatic contralateral ears [20] . In addition, electrocochleography is a neurophysiological test that correlates with EH in the cochlea; however, the fluctuating symptoms limit their applicability as diagnostic tool in the early course of MD [21] .
Familial MD
Familial MD should be considered if at least one other relative (first or second degree) fulfills all the criteria of definite or probable MD [22] . Familial MD is observed in 8%-9% of sporadic cases in populations of European descent [22, 23] . It has been described in Caucasians from United Kingdom [24] , Brazil [25] , Sweden [26] , Finland [23, 27] , Germany [28] and Spain [23] . Although most families described have an autosomal dominant pattern of inheritance, familial MD shows genetic heterogeneity, and mitochondrial and recessive inheritance patterns are also observed in some families [22] . Mutations in DTNA and FAM136A genes have been described in familial MD [29] . A family history of SNHL, migraine or recurrent vertigo in several members of the family would justify a familial investigation of these patients to confirm if any of them fulfill diagnostic criteria for MD.
Overlap with vestibular migraine
Some studies suggest that migraine is more common in patients with MD than in healthy controls [30, 31] . Patients with features of both MD and vestibular migraine have been repeatedly reported [32] . In fact, migraine and MD can be inherited as a symptom cluster [33] . Fluctuating hearing loss, tinnitus and aural pressure may occur in vestibular migraine, but SNHL does not typically progress to severe hearing loss over the years in migraine. When hearing loss develops in vestibular migraine, it is often bilateral [32] whereas involvement of both ears from the onset is rare in MD [34] . Although migraine headache and phonophobia may be present during MD attacks, the pathophysiological relationship between vestibular migraine and MD is unclear. Some authors have suggested a common pathophysiology, perhaps linked to an ion channel dysfunction [35] and endolymphatic hydrops has been reported in patients with vestibular migraine and auditory symptoms [36] .
Autoimmune inner ear disease
Autoimmune inner ear disease (AIED) is a syndrome of rapidly progressive, often fluctuating, bilateral SNHL over a period of days to months. Vestibular symptoms may be present in almost 50% of patients, and a systemic autoimmune disease coexists in 15%-30% of patients [37] . In some cases, AIED begins as sudden SNHL in one ear progressing rapidly to the second ear with tinnitus and balance symptoms, which may resemble MD [38] . Rare cases of otologic syphilis and neuroborreliosis can present similarly.
Transient ischemic attack and stroke
Combined audio-vestibular symptoms are also a hallmark of transient ischemic attack (TIA) and stroke, since the blood supply to the inner ear derives from the vertebro-basilar circulation [39] . Such symptoms typically result from ischemia in the anterior inferior cerebellar artery (AICA) territory [40, 41] , since the internal auditory artery (IAA) most often arises as a branch of the AICA. However, the IAA can arise directly from the basilar artery in 15%-20% of individuals [42] , so mixed vestibular and auditory symptoms may be a harbinger of basilar artery occlusion.
Patients may present initially with transient or episodic symptoms (TIA) that culminate in stroke with acute permanent hearing loss, permanent vestibular loss, or both [43] . Transient dizziness, hearing loss, and/or tinnitus may occur as a premonitory TIA preceding acute audio-vestibular loss due to AICA infarction in up to 42% of cases. [40, 43] Although neurologic symptoms such as facial palsy or hemiparesis can occur in patients with basilar strokes, some patients with partial syndromes can manifest with isolated audio-vestibular symptoms almost indistinguishable from MD [44] . Furthermore, TIA symptoms can culminate in isolated labyrinthine infarction (without cerebellar or brainstem involvement) [45] .
Most strokes after TIA occur within 90 days [45] , but isolated vestibular symptoms have been reported for up to two years or more preceding stroke. Therefore, great care should be taken in patients with symptoms that are very recent in total illness duration (< 3 months-6 months, especially < 30 days), particularly if the total number of episodes is relatively small (e.g., < 5) or has followed an escalating temporal profile of episode frequency ("crescendo TIA") [44] . Care should also be taken in patients with known vascular risk factors (including older age at first onset) and those presenting to acute care settings such as the emergency department. When clinically-important doubt exists, appropriate diagnostic testing for stroke and TIA (e.g., MRI with magnetic resonance angiography) should be considered. The first episode of MD may not differ from a TIA, and sudden SNHL associated with vertigo may be caused by a labyrinthine infarction.
